Non-AIDS-related Kaposi's sarcoma: A single-institution experience

Table 1 Patient characteristics n (%)

	Patients number
Sex
Male	21 (65.6)
Female	11 (34.4)
Comorbidities
Diabetes	6 (18.7)
Alzheimer’s	2 (6.3)
Hypertension	15 (46.9)
Kaposi variant
Classic	27 (84.3)
Iatrogenic	5 (15.6)
Anatomic site
Limbs	24 (75)
Limbs and trunk	5 (15.6)
Scrotum	1 (3.1 )
Glans	1 (3.1 )
Lymph node involvement	1 (3.1)
Number of lesions
1	0
2	0
3	0
> 3	32 (100)
Stage
Stage IIb	18 (56.2)
Stage III-IV	14 (43.7)

Table 2 Chemotherapy agents employed in the sample population n (%)

	Patients number
Sytemic treatment1
Vinblastine	17 (53.1)
Pegylated liposomal doxorubicin	8 (25)
Paclitaxel	5 (15.6)
Gemcitabine	1 (3.1)
Vinorelbine	1 (3.1)
Overall number of lines of systemic treatment received by the patient
1 line	26 (81.2)
> 1 line	6 (18.8)

¹The first systemic treatment delivered at our institution is reported.

Table 3 Response to treatment n (%)

Response
Complete response	4 (12.4)
Partial response	10 (31.5)
Stable disease	16 (50)
Progressive disease	2 (6.2)
Progression-free survival, mo (range)	11.7 (3-48)
Overall survival, mo (range)	28.5 (12-48)

Disease control rate is 93.7%.

Table 4 Cox proportional hazard regression for progression-free survival

Characteristic	Hazard ratio (95%CI)	P value
Univariable
Stage (II vs III/IV)	1.63 (0.74-3.57)	0.22
Cutaneous lesion (macules vs nodules)	3.09 (1.18-8.13)	0.01
Extent (lower limb only vs other parts of the body)	1.61 (0.72-3.59)	0.24
Symptoms (no vs yes)	0.72 (0.32-1.62)	0.44
Age	0.97 (0.93-1.01)	0.16
Sex (female vs male)	0.73 (0.32-1.69)	0.47
Multivariable
Cutaneous lesion (nodular/papular/macules vs macules only)	3.09 (1.18-8.13)	0.013